Abstract
Many rheumatic diseases can be associated with different complications in kidneys and urinary tract. The goal of this chapter is to provide a summary of renal manifestations in rheumatic diseases that is easily accessible by students, residents, and practitioners.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
1 Introduction
Many rheumatic diseases can be associated with different complications in kidneys and urinary tract. The goal of this chapter is to provide a summary of renal manifestations in rheumatic diseases that is easily accessible by students, residents, and practitioners.
The material presented provides a simple approach to patients presenting with renal and rheumatic manifestations. It is not meant to be an exhaustive review.
It presents a stepwise approach to the evaluation of proteinuria and hematuria in patients with rheumatic diseases. It also provides a summary on the renal complications of rheumatic diseases. The chapter also discusses lupus nephritis (LN) in more detail as it is common and severe manifestation of systemic lupus erythematosus with increased risk of death and end-stage renal disease.
2 Objectives
By the end of this chapter, you should be able to:
-
1.
Construct a diagnostic approach to patients with proteinuria or hematuria.
-
2.
Diagnose and manage lupus nephritis (LN).
-
3.
Discuss renal involvement in different rheumatic diseases.
-
4.
Review the common side effects of antirheumatic medications on kidney function.
3 Proteinuria
Proteinuria screening among populations is based on measurement of albumin in random urine dipstick test. Most adolescents who have proteinuria through dipstick test do not have renal disease, and this proteinuria usually resolves on repeat testing. However, prolonged proteinuria is suggestive of kidney disease in patients with diabetes mellitus, hypertension, primary renal disease, SLE, or other systemic illnesses [1].
Proteinuria greater than 200Â mg/24Â h is considered abnormal. Urine protein excretion ranging between 200 and 3000Â mg/24Â h is termed sub-nephrotic range proteinuria. Nephrotic range proteinuria is typically more than 3000Â mg/24Â h.
Proteinuria is an important indicator of renal disease activity and progression. It reflects an underlying pathology causing a change in the permeability properties of the glomerular filtration barrier [1].
A stepwise approach that may help physicians detect and evaluate benign and pathological causes of proteinuria is illustrated in Fig. 14.1.
4 Hematuria
Microscopic hematuria refers to the presence of erythrocytes in urine that can be exclusively detected by microscopic exam or dipstick analysis. It is a frequent reason for referral to urology or nephrology. It is often asymptomatic and found incidentally on routine urine examination.
Macroscopic (grossly visible) hematuria is more commonly associated with malignancy than microscopic hematuria. For this reason, a full investigation, including upper tract imaging and cystoscopy for the lower tract, for all patients with macroscopic hematuria is usually required.
Opinions regarding which patients with microscopic hematuria should be evaluated and need to be investigated remain controversial [2, 3].
Figures 14.2 and 14.3 provide simplified approaches to detect and evaluate significant microscopic hematuria according the recent guidelines [2, 3].
5 Renal Involvement in Different Rheumatic Diseases
Rheumatic diseases are frequently associated with renal complications. These complications include vascular, glomerular, and tubulointerstitial changes.
Drug-induced renal impairment should be included in the differential diagnosis of renal complications in a rheumatic patient.
Renal involvement clinically manifests in many different ways. The spectrum ranges from slight functional disorders such as slight erythrocyturia/proteinuria with normal renal function to rapidly progressive renal failure. Table 14.3 provides a summary of renal involvement in different rheumatic diseases.
6 Lupus Nephritis (LN)
Renal involvement is common in SLE. It is the leading cause of morbidity and mortality in patients with lupus, characterized by the loss of self-tolerance, production of autoantibody, and development of immune complexes that deposit in the kidney to induce nephritis. Proteinuria is one of the most commonly observed abnormalities in patients with lupus nephritis [6]. Figure 14.4 provides an overview of pathogenesis, clinical manifestations, and complications of lupus nephritis.
6.1 Diagnostic Criteria
Criteria for lupus nephritis in patients with SLE include any of the following conditions (Table 14.1):
-
1.
Persistent proteinuria.
-
500Â mg/24Â h protein
-
3+ protein on urine dipstick
-
Spot urine protein/creatinine ratio > 0.5 mg/mg.
-
-
2.
Cellular casts.
-
3.
Active urinary sediment (> 5 red blood cells/high power field [RBC/hpf], > 5 white blood cells[WBC]/hpf in the absence of infection, or cellular casts limited to RBC or WBC casts).
-
4.
Renal biopsy: Immune complex-mediated glomerulonephritis compatible with lupus nephritis.
-
5.
Opinion of rheumatologist or nephrologist [11].
6.2 Treatment
The American College of Rheumatology (ACR) recommends treatment according to the International Society of Nephrology/Renal Pathology Society (ISN/ RPS) classification of lupus nephritis. (Check sect. 3 for full presentation of the recommendation for management guidelines). Response to treatment is based on several factors including age, gender, location, and race/ethnicity (Table 14.2) [14].
6.3 Adjunctive Treatments
-
1.
Hydroxychloroquine for all patients with SLE unless contraindicated.
-
2.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers if proteinuria ≥500 mg/24 h [15]
-
3.
Statin therapy if LDL cholesterol >100Â mg/dL (2.6Â mmol/L).
-
4.
Control hypertension at a target of ≤130/80 mm Hg [11]
Note: Patients with lupus should remain on antimalarial therapy even during disease quiescence as it was shown to be associated with associated with reduced risk of renal damage, improved survival, and decreased incidence of lupus flares [16].
7 Sjögren’s Syndrome
Sjögren’s syndrome is a chronic inflammatory disorder characterized by lymphocytic infiltration of the lacrimal and salivary glands which result in dryness of the eyes and mouth [17]. Systemic features may include arthritis, renal, hematopoietic, pulmonary involvement, and vasculitis (Fig. 14.5). These manifestations are secondary to vasculitis, autoantibody-mediated mechanisms, or lymphocytic infiltration of the target organs. The prevalence of renal involvement ranges from 2 to 67% [22].
8 Cryoglobulinemic Syndrome (CG)
Cryoglobulinemic vasculitis is an immune-complex-mediated disease caused by the deposition of cryoglobulins in the small- and medium-sized arteries and veins. Renal involvement is noted in around 20% of patients with mixed cryoglobulinemic vasculitis and usually diagnosed 2.5Â years after the disease onset. Membranoproliferative glomerulonephritis is reported in around 80% of patients [23]. Figure 14.6 provides an overview of renal involvements in CG.
9 Scleroderma
Scleroderma is manifested by widespread progressive fibrosis of the skin and internal organs due to accumulation of collagen. Renal involvement occurs in around half of the patients and is manifested as mild proteinuria, worsening kidney function, and/or hypertension (Fig. 14.7) [26]. Scleroderma renal crisis is the most serious renal manifestation which occurs in 5 to 10% of patients with systemic sclerosis, more commonly in diffuse cutaneous systemic sclerosis [27].
9.1 Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a systemic inflammatory disorder of unknown etiology that primarily involves the joints. It has been reported that the annual incidence of rheumatoid arthritis is around 40 per 100,000. Females are affected two to three times more often than males, and the peak onset is between 50 and 75Â years of age [28]. An observational study has shown that the incidence of impaired kidney function is higher in patients with rheumatoid arthritis; these changes were anticipated by many factors like cardiovascular disease, dyslipidemia, elevated sedimentation rate in the first year of rheumatoid arthritis, and NSAIDs use [29]. Figure 14.8 provides an overview of renal involvement in RA.
9.2 Renal Involvement in Vasculitis
9.2.1 Polyarteritis Nodosa (PAN)
It is a systemic necrotizing vasculitis of medium-sized and occasionally small vessels [34]. It is a rare disease and characterized by the absence of antineutrophil cytoplasmic antibodies (ANCA) [34]. Any organ can be affected including the kidneys (renal artery involvement is common and leads to stenosis, hypertension, and eventually chronic kidney disease) (Fig. 14.9). This disease spares the lungs [34]. Most cases are idiopathic; however, 33% of cases are associated with chronic HBV infection [34]. Renal disease is the most common cause of death. It is fatal if left untreated, but has favorable response to treatment [34].
9.3 Eosinophilic Granulomatosis with Polyangiitis EGPA (Churg-Strauss)
It is a systemic necrotizing vasculitis that affects small-sized muscular arteries [35]. It is a rare disease and characterized by the presence of antineutrophil cytoplasmic antibodies (ANCA) [35]. Asthma, peripheral eosinophilia, and granulomas on histology are common associations with this disease [35]. Renal involvement can lead to pauci-immune rapidly progressive glomerulonephritis (Fig. 14.10) [35].
9.4 Granulomatosis with Polyangiitis GPA (Wegener’s) and Microscopic Polyangiitis (MPA)
These are systemic vasculitides of the medium- and small-sized arteries, as well as the venules and arterioles [29]. They are known to cause many renal complications, e.g., glomerulonephritis, acute kidney injury, and proteinuria (Fig. 14.11) [29, 30].
Rapidly progressive glomerulonephritis is a common and severe feature with Wegener’s granulomatosis or proteinase-3 (PR3)-ANCA vasculitis, and it might lead to end-stage renal diseases [29, 30]. In addition, necrotizing granulomatous inflammation is the histopathologic hallmark of GPA [29, 30]. Microscopic polyangiitis or myeloperoxidase (MPO)-ANCA vasculitis are associated with chronic renal injury more than glomerulonephritis [29, 30].
9.5 Henoch-Schönlein Purpura (HSP) (IgA Vasculitis)
It is a systemic vasculitis of the small-sized blood vessels (the post-capillary venules), characterized by the deposition of IgA-containing immune complexes [40].
IgA vasculitis is considered the most common systemic vasculitis in children [40]. Renal involvement occurs in 20% to 100% of patients. HSP nephritis is common and generally mild in children (particularly young children) (Fig. 14.12). It is mainly presented with microscopic hematuria or proteinuria [40] (Table 14.3).
9.6 Renal Side Effects of DMARDs and NSAIDs
Renal toxicity of disease-modifying antirheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs) varies depending on the age and the kidney function of the patient. Side effects are commonly observed in elderly patients with compromised kidney function. Therefore, the use of NSAID should be avoided in patients with chronic kidney disease. Cyclosporine, gold, and penicillamine are associated with more serious renal side effects. Fortunately, gold and penicillamine are now very rarely used for the treatment of rheumatic diseases. Others like methotrexate, azathioprine, antimalarials, sulfasalazine, and leflunomide are safer with relatively less renal toxicity [35, 36]. Table14.4 summarized the renal side effects of commonly used drugs in rheumatic diseases.
References
Ellam TJ, El Nahas M. Proteinuria thresholds are irrational: a call for proteinuria indexing. Nephron Clin Pract. 2011;118(3):c217–24.
Wollin T, Laroche B, Psooy K. Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. Can Urol Assoc J. 2009;3(1):77–80.
Grossfeld GD, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American urological association best practice policy--part I: definition, detection, prevalence, and etiology. Urology. 2001;57(4):599–603.
Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26(1):61–72.
McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ. 2006;333(7568):581–5.
Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton). 2005;10(2):174–9.
Austin, H.A., 3rd, et al., Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int, 1994. 45(2): p. 544–550.
Tisseverasinghe A, et al. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum. 2006;54(7):2211–9.
Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2005;14(1):25–30.
Loizou S, et al. Significance of anticardiolipin and anti-beta(2)-glycoprotein I antibodies in lupus nephritis. Rheumatology (Oxford). 2000;39(9):962–8.
Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens. 2005;14(1):1–8.
KDIGO Clinical Practice Guideline for Glomerulonephritis. http://www.kidney-international.org, 2012. 2(2): p. 143.
Liu LL, et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012;72(11):1521–33.
Duran-Barragan S, et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093–6.
Pons-Estel GJ, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830–9.
Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64(3):347–54.
Aasarod K, et al. Renal involvement in primary Sjogren's syndrome. QJM. 2000;93(5):297–304.
Bossini N, et al. Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. Nephrol Dial Transplant. 2001;16(12):2328–36.
Maripuri S, et al. Renal involvement in primary Sjogren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol. 2009;4(9):1423–31.
Ramos-Casals M, et al. Topical and systemic medications for the treatment of primary Sjogren's syndrome. Nat Rev Rheumatol. 2012;8(7):399–411.
Pertovaara M, Korpela M, Pasternack A. Factors predictive of renal involvement in patients with primary Sjogren's syndrome. Clin Nephrol. 2001;56(1):10–8.
Dammacco F, et al. The cryoglobulins: an overview. Eur J Clin Investig. 2001;31(7):628–38.
Denton CP, et al. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48(Suppl 3):iii32–5.
Traub YM, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983;62(6):335–52.
Steen VD, et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol. 2005;32(4):649–55.
Denton C, et al. Renal complications and scleroderma renal crisis. Rheumatology. 2009;48(suppl_3):iii32–5.
Sullivan PW, et al. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol. 2010;37(3):544–9.
Hickson LJ, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63(2):206–13.
Turesson C, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29(1):62–7.
Turesson C, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):59–64.
Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70(4):246–56.
Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013;11:95.
Agard C, et al. Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? Arthritis Rheum. 2003;49(5):709–15.
Sinico RA, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47(5):770–9.
de Lind van Wijngaarden RA, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17(8):2264–74.
Hauer HA, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62(5):1732–42.
Berden AE, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–36.
Pagnoux C, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.
Halling SF, Soderberg MP, Berg UB. Henoch Schonlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol. 2005;20(1):46–51.
Acknowledgments
The authors would like to thank Dr. Waleed Hafiz for his assistance in the development of this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2021 The Author(s)
About this chapter
Cite this chapter
Alobaidi, S., Alotaibi, M., Al-Zahrani, N., Al-Dhaheri, F. (2021). Renal System and Rheumatology. In: Almoallim, H., Cheikh, M. (eds) Skills in Rheumatology . Springer, Singapore. https://doi.org/10.1007/978-981-15-8323-0_14
Download citation
DOI: https://doi.org/10.1007/978-981-15-8323-0_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-8322-3
Online ISBN: 978-981-15-8323-0
eBook Packages: MedicineMedicine (R0)